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Gait mechanics in patients with chronic
obstructive pulmonary disease
Jennifer M Yentes1*, Kendra K Schmid2, Daniel Blanke1, Debra J Romberger3,4, Stephen I Rennard4 and
Nicholas Stergiou1,2
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by the frequent association of disease
outside the lung. The objective of this study was to determine the presence of biomechanical gait abnormalities in
COPD patients compared to healthy controls while well rested and without rest.
Methods: Patients with COPD (N = 17) and aged-matched, healthy controls (N = 21) walked at their self-selected
pace down a 10-meter walkway while biomechanical gait variables were collected. A one-minute rest was given
between each of the five collected trials to prevent tiredness (REST condition). Patients with COPD then walked at a
self-selected pace on a treadmill until the onset of self-reported breathlessness or leg tiredness. Subjects immediately
underwent gait analysis with no rest between each of the five collected trials (NO REST condition). Statistical models
with and without covariates age, gender, and smoking history were used.
Results: After adjusting for covariates, COPD patients demonstrated more ankle power absorption in mid-stance
(P = 0.006) than controls during both conditions. Both groups during NO REST demonstrated increased gait speed
(P = 0.04), stride length (P = 0.03), and peak hip flexion (P = 0.04) with decreased plantarflexion moment (P = 0.04) and
increased knee power absorption (P = 0.04) as compared to REST. A significant interaction revealed that peak ankle
dorsiflexion moment was maintained from REST to NO REST for COPD but increased for controls (P < 0.01). Stratifying
by disease severity did not alter these findings, except that step width decreased in NO REST as compared to REST
(P = 0.01). Standardized effect sizes of significant effects varied from 0.5 to 0.98.
Conclusions: Patients with COPD appear to demonstrate biomechanical gait changes at the ankle as compared to
healthy controls. This was seen not only in increased peak ankle power absorption during no rest but was also
demonstrated by a lack of increase in peak ankle dorsiflexion moment from the REST to the NO REST condition as
compared to the healthy controls. Furthermore, a wider step width has been associated with fall risk and this could
account for the increased incidence of falls in patients with COPD.
Keywords: Pulmonary disease, Locomotion, Joint kinematics, Joint kinetics, Biomechanics
Background
Chronic obstructive pulmonary disease (COPD) is a
worldwide health concern and is one of the few causes
of death that is on the rise [1]. COPD affects more than
the lungs and Fabbri and Rabe have emphasized the
‘systemic and complex abnormalities’ affecting peripheral
systems in patients with COPD [2]. One extra-pulmonary
manifestation of COPD is abnormal skeletal muscle
structure (i.e., muscular dysfunction). Patients with
COPD suffer from abnormal body mass alterations,
muscle wasting/atrophy, impaired energy production
and metabolic performance, and increased susceptibility
to muscle fatigue and weakness [3-11].
Possibly related to abnormal skeletal muscle structure
is the decline in ambulatory activity that is common in
patients with COPD. Using the 6-minute walk distance
test, patients with COPD walked a significantly shorter
distance than aged-matched controls [12] and hospitalized
patients with COPD walked less than 10 minutes/day
during hospitalization and only up to 15 minutes/day
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after one month of discharge [13]. One third of patients
with severe COPD walked less than 15 minutes/day [14]
and when compared over a 12-hour time frame, walked
50% less than age-matched controls [15]. Ambulatory
activity may be limited in patients with COPD due to
neural and/or leg fatigue [16-18], suggesting muscular
dysfunction as a major contributor to limitation of
ambulation [19].
Gait abnormalities may be present in COPD that are
distinct from muscular weakness. Specifically, abnormal-
ities in the biomechanics of the gait cycle may contribute
to altered ambulation. Our previous examination into
existing data consisting of subjective reports of gait ab-
normalities in patients with COPD, demonstrated that
the presence of COPD is associated with the report of a
limp, shuffle or other walking abnormality, which ap-
peared to be related to COPD severity [20]. However,
objective analysis of gait mechanics in patients with
COPD has yet to be completed. Annegarn and col-
leagues used an accelerometer to assess gait during a 6-
minute walk test and demonstrated that cadence, walk
intensity and variability were related to the distance
walked in COPD patients [21]. More detailed analysis of
lower extremity joint muscular responses can be pro-
vided using advanced biomechanical analysis in the form
of joint angles, moments, and powers [22-24]. Joint mo-
ments can determine the net response of all muscle
groups in the lower extremities revealing crucial COPD-
related adaptations. Whereas, joint powers determine
the net contribution of all muscle groups at that joint.
This analysis has been used extensively to understand
the control mechanisms in healthy individuals and in
gait abnormalities of patients with cerebral palsy [25-27],
stroke [28-30], head injury [31-33] and other neuromus-
cular disorders [34-36].
Hence, the overall objectives of this study were to ob-
jectively and comprehensively characterize gait abnormal-
ities present in patients with COPD. Utilizing the
mechanical analysis of joint angles, moments, and powers,
in addition to spatiotemporal gait parameters, in persons
with COPD and aged-matched controls, the presence of
abnormal gait patterns was assessed. Based upon our pre-
vious work [20], it was hypothesized that patients with
COPD would demonstrate decrements in their gait as
compared to healthy controls. Gait analysis was performed
in two conditions, REST and NO REST. The NO REST
condition was provided to the subjects to investigate an
activity-induced condition. Specifically, it was hypothe-
sized that a lack of rest would exacerbate alterations in
gait mechanics. Furthermore, our previous study indicated
that disease severity, age, gender, and smoking history may
be associated with gait abnormalities in patients with
COPD. Thus, statistical models were used to limit the
effects of these potential confounding variables.
Methods and materials
Patients with COPD were recruited from the Pulmonary
Clinical Studies Unit and general clinics of local hospi-
tals. A FEV1/FVC ratio of 0.7 was used to define the
presence of COPD [37]. Participants were excluded if
there was a history of back or lower extremity injury or
surgery that affected the subject’s mobility or any other
process limiting the ability to walk, including neuro-
logical disease or impairment. In total, 17 patients with
COPD and 21 age-, height- and weight-matched healthy
controls were consented and participated in this study
(Table 1). The University Institutional Review Board and
the Institutional Review Board at the Omaha Veterans’
Affairs Medical Center approved all procedures and
written informed consent was obtained from all patients.
Protocol
To assess gait, reflective markers were placed on defined
anatomical locations, bilaterally, according to a modified
Helen Hayes marker set [38]. Participants were asked to
walk through a 10-meter walkway at a normal pace. To en-
sure that a complete footfall would be collected during each
trial, starting positions for each limb were determined prior
to data collection. Five trials were collected for each limb,
10 trials total. The 3D marker trajectories were collected
with a high-speed motion capture system (Motion Analysis
Corp., Santa Rosa, CA; 60 Hz). Ground reaction force data
from heel contact to toe off were collected using a piezo-
electric force plate (Kistler Instrument Corp., Winterthur,
Switzerland; 600 Hz). All participants were given a mini-
mum one-minute rest between each trial during the data
collection (RESTcondition).
All patients with COPD were then asked to determine
their self-selected pace on a treadmill at 0% incline. They
then walked at their chosen self-selected pace at 10% in-
cline until the onset of self-reported breathlessness or
muscle tiredness (reported as either the development of
shortness of breath or the onset of subjective muscular
fatigue). Subjects were asked to walk until they felt like
they could not continue any further due to breathlessness
or muscle tiredness. This was a completely subjective in-
terpretation. Motion capture data was not collected while
the subject walked on the treadmill. Once self-reported
breathlessness or muscle tiredness was reported, they were
immediately removed from the treadmill and asked to
walk through the 10-meter walkway, 5 times for each limb,
with no rest in between trials (NO REST condition). A
subset (n = 5) of healthy controls also went through the
NO REST condition in order to investigate the main effect
of condition in non-COPD group. Since these subjects
were not expected to indicate tiredness or breathlessness,
they were asked to walk for 15 minutes at a self-selected
speed on the treadmill at a 10% grade.
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Data analysis
Gait variables were calculated from the five trials during
the stance phase of walking for each subject (Table 2).
Each marker’s three directions were filtered using the
Jackson algorithm [39] with cutoff values ranging from
2-8Hz. Visual 3D (C-Motion, Inc., Germantown, Mary-
land) was used for calculation of joint angles, moments,
and powers. A standing calibration was used to align the
local reference frames of the segments to the global ref-
erence frame. A hybrid model was built using anthropo-
metric data from Dempster [40]. Custom programs
(MatLab 2007, Mathworks, Inc., Concord, MA) were
used to pick peak angles, moments, and powers from
calculated joint curves. In the REST condition, two
healthy controls and one patient with COPD did not
have a sufficient number of strides collected for spatio-
temporal data analysis. One healthy control and one pa-
tient with COPD did not have a sufficient number of
strides collected for spatiotemporal data analysis in the
NO REST condition. They were removed for spatiotem-
poral analysis even though they were included in the
kinematic and kinetic analysis. One patient with COPD
could not complete the NO REST condition due to
exhaustion.
All variables were checked for normality and group
means of each dependent variable (Table 2) were calculated
for each group (control and COPD) and for each condition
(REST and NO REST). Four linear models were utilized on
each dependent variable in Table 2:
1) A 2x2 linear model with repeated measures for
condition was used to compare outcomes between
group (all COPD vs control) and condition (REST vs
NO REST) and to assess the group by condition
interaction.
2) The covariates of age, gender and smoking history
were added to model #1.
3) A 3x2 linear model with repeated measures for
condition was used to compare outcomes between
group (mild/moderate COPD vs severe/very severe
COPD vs control) and condition (REST vs NO
REST) and to assess the group by condition
interaction. Disease severity was defined using
GOLD standards [37]. Tukey’s method was used to
adjust for multiple comparisons.
4) The covariates of age, gender and smoking history
were added to model #3.
All statistical analysis was done using SAS version 9.3
(SAS Institute Inc., Cary, NC, USA). To control for the
unbalanced group sizes, the LS Means were calculated
and compared using SAS PROC MIXED. The significance
Table 1 Subject characteristics
Control mean (SD) n = 21 COPD mean (SD) n = 17 P
Gender (n) Male = 10 Male = 11
Age (years) 65.33 (7.67) 63.77 (8.55) 0.56
Height (cm) 165.89 (16.43) 171.97 (11.79) 0.21
Weight (kg) 78.85 (18.08) 90.58 (25.62) 0.11
FEV1/FVC 0.74 (0.04) 0.51 (0.16) <0.001*
FEV1% Predicted 101.71 (11.00) 50.18 (21.0) <0.001*
Smoking History (n)
Current Smoker 2 5
Ex-Smoker 7 11
Never Smoker 12 1
Control Rest Mean (SD) Control No Rest Mean (SD) COPD Rest Mean (SD) COPD No Rest Mean (SD)
Speed (m/s) 1.09 (0.16) 1.07 (0.25) 1.11 (0.17) 1.15 (0.18)
Step Length (m) 0.66 (0.07) 0.65 (0.09) 0.66 (0.06) 0.66 (0.06)
Step Width (m) 0.11 (0.03) 0.11 (0.03) 0.12 (0.04) 0.11 (0.04)
Step Time (sec) 0.60 (0.06) 0.62 (0.06) 0.59 (0.06) 0.58 (0.06)
Stance Time (sec) 0.70 (0.09) 0.73 (0.08) 0.70 (0.10) 0.69 (0.09)
Support Time (sec) 0.11 (0.03) 0.12 (0.02) 0.12 (0.04) 0.11 (0.03)
Stride Length (m) 1.32 (0.14) 1.33 (0.17) 1.31 (0.13) 1.33 (0.13)
Stride Time (seconds) 1.19 (0.13) 1.22 (0.12) 1.18 (0.13) 1.15 (0.11)
Note: * indicates significance P < 0.05.
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level was set at P < 0.05. Standardized effect sizes (ES)
were estimated as difference in LSMeans divided by the
standard deviation of the difference for all significant
findings.
Results
For model #1, a main effect of group was found for peak
hip power absorption at mid-stance (F1, 36 = 4.71, P =
0.04, ES = 0.7) in which patients with COPD absorb less
power than do controls. Several significant main effects
of condition were also found. In the REST condition,
peak knee power absorption during early stance (F1, 19 =
4.70, P = 0.04, ES = 0.5; Figure 1) was increased and peak
hip flexion angle (F1, 19 = 4.71, P =0.04, ES = 0.5; Figure 2),
peak knee flexion moment (F1, 19 = 5.07, P = 0.04, ES = 0.5;
Figure 3) and peak plantarflexion moment (F1, 19 = 5.12,
P = 0.04, ES = 0.5; Figure 3) were significantly decreased
as compared to the NO REST condition. In addition,
gait speed and stride length both significantly increased
in the NO REST condition as compared to the REST
condition (F1, 17 = 4.76, P = 0.04, ES = 0.5 & F1, 17 = 5.86,
P = 0.03, ES = 0.6 respectively). Lastly, a significant
interaction was found for peak ankle dorsiflexion mo-
ment in early stance (F1, 19 = 16.57, P = 0.007; Figure 4A).
Patients with COPD slightly decreased their dorsiflex-
ion moment from REST to NO REST (Mean ± standard
error: −0.32 ± 0.32 to −0.31 ± 0.02 Nm/kg), whereas
healthy controls increased their dorsiflexion moment
from REST to NO REST (−0.35 ± 0.02 to −0.40 ±
0.02 Nm/kg).
When covariates were added (model #2), the hip no
longer demonstrated a group effect and instead a main
Table 2 Dependent variables and their descriptions
Dependent variable Description
Speed (m/s) Measured as the derivative of the position of the sacral marker.
Step Length (m) Anterior-posterior distance from the heel strike of the right foot to the heel strike of the left foot.
Step Width (m) Medial-lateral distance from the heel strike of the right foot to the heel strike of the left foot.
Step Time (seconds) Time from the heel strike of the right foot to the heel strike of the left foot.
Stance Time (seconds) Time between heel strike and toe off for the right foot.
Double Support Time (seconds) Timing of the heel strike of the left foot to the toe off of the right foot (terminal double support).
Stride Length (m) Anterior-posterior distance from two consecutive right heel strikes.
Stride Time (seconds) Time between two consecutive right heel strikes.
Peak Plantarflexion Angle (deg) Minimum angle during early stance.
Peak Dorsiflexion Angle (deg) Maximum positive angle during late stance.
Peak Knee Flexion Angle (deg) Maximum positive angle during early to mid stance.
Peak Knee Extension Angle (deg) Minimum angle (close to zero) during mid to late stance.
Peak Hip Flexion Angle (deg) Maximum positive angle at very early stance.
Peak Hip Extension Angle (deg) Minimum angle (close to zero) during late stance.
Peak Dorsiflexion Moment (N*m/kg) Minimum rotational force during early stance.
Peak Plantarflexion Moment (N*m/kg) Maximum rotational force during late stance.
Peak Knee Extension Moment (N*m/kg) Maximum rotational force during mid stance.
Peak Knee Flexion Moment (N*m/kg) Minimum rotational force during mid to late stance.
Peak Hip Extension Moment (N*m/kg) Maximum rotational force during very early stance.
Peak Hip Flexion Moment (N*m/kg) Minimum rotational force during late stance.
Peak Ankle Power Absorption 1 (W/kg) Minimum energy absorbed during early stance.
Peak Ankle Power Absorption 2 (W/kg) Minimum energy absorbed during mid to late stance.
Peak Ankle Power Generation (W/kg) Maximum energy generated during late stance.
Peak Knee Power Absorption 1 (W/kg) Minimum energy absorbed during early to mid stance.
Peak Knee Power Generation (W/kg) Maximum energy generated during mid stance.
Peak Knee Power Absorption 2 (W/kg) Minimum energy absorbed during late stance.
Peak Hip Power Generation 1 (W/kg) Maximum energy generated during early stance.
Peak Hip Power Absorption (W/kg) Minimum energy absorbed during mid to late stance.
Peak Hip Power Generation 2 (W/kg) Maximum energy generated during late stance.
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effect for group was found at the ankle. Peak ankle
power absorption during mid-stance was significantly
increased (F1, 32 = 8.80, P = 0.006, ES = 0.98) in patients
with COPD as compared to controls. Significant main
effects of condition found similar to those found in
model #1, with the exception of the peak knee power
absorption in early stance. Peak plantarflexion moment
(F1, 19 = 5.99, P = 0.02, ES = 0.53) was decreased and
peak hip flexion angle (F1, 19 = 4.98, P =0.04, ES = 0.5)
and peak knee flexion moment (F1, 19 = 5.22, P = 0.03,
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Figure 1 Sagittal plane joint power mean ensemble curves for the stance phase of gait for the: A) ankle, B) knee, and C) hip. Positive
values represent energy generation. Peak joint powers are shown in the bar graphs for the healthy controls rest (solid gray), healthy controls no
rest (striped gray), COPD rest (solid black), and COPD no rest (striped black). Note: * indicates significance (P < 0.05) at the indicated peak hip
power absorption at mid stance between the healthy controls and patients with COPD. This finding was significant when covariates were not
added to the model. Patients with COPD demonstrated less hip power absorption as compared to controls. § indicates significance (P < 0.05) at
the indicated peak ankle power absorption at mid stance between healthy controls and patients with COPD when covariates were added to
the model.
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Figure 2 Sagittal plane joint angle mean ensemble curves for the stance phase of gait for the: A) ankle, B) knee, and C) hip. Positive
values represent dorsiflexion and flexion. Peak joint angles are shown in the bar graphs for the healthy controls rest (solid gray), healthy controls
no rest (striped gray), COPD rest (solid black), and COPD no rest (striped black). Note: ^ indicates a significant (P < 0.05) main effect of condition
(rest vs no rest) in the model without covariates whereas, # indicates the same main effect but in the model in which the covariates age, gender
and smoking history have been added. In both models, peak hip flexion angle is increased in the no rest condition.
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Figure 3 Sagittal plane joint moment mean ensemble curves for the stance phase of gait for the: A) ankle, B) knee, and C) hip. Positive
values represent plantarflexion and extension. Peak joint moments are shown in the bar graphs for the healthy controls rest (solid gray), healthy
controls no rest (striped gray), COPD rest (solid black), and COPD no rest (striped black). Note: ^ indicates a significant (P < 0.05) main effect of
condition (rest vs no rest) in the model without covariates whereas, # indicates the same main effect but in the model in which the covariates
age, gender and smoking history have been added. In both models, peak knee flexion moment is increased and peak ankle plantarflexion
moment is decreased in the no rest condition. ¥ indicates a significant (P < 0.05) interaction.
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ES = 0.5) were significantly increased in NO REST as
compared to REST. Gait speed and stride length both
significantly increased in the NO REST condition as
compared to the REST condition (F1, 17 = 4.80, P = 0.04,
ES = 0.5 & F1, 17 = 5.80, P = 0.03, ES = 0.6, respectively).
The interaction for peak ankle dorsiflexion moment in
early stance maintained significance when covariates
were added to the model as well (F1, 19 = 17.10, P =
0.0006) (Figure 4B). Patients with COPD did not change
their dorsiflexion moment from REST to NO REST
(Mean ± standard error: −0.34 ± 0.03 Nm/kg for both)
but the healthy controls increased their dorsiflexion
moment across conditions (−0.33 ± 0.02 to −0.39 ±
0.03 Nm/kg).
In model #3, covariates were not used and patients
with COPD were stratified into disease severity classifi-
cations: mild/moderate and severe/very severe and com-
pared to controls. No main effect for group was found.
Main effects for condition were found for similar vari-
ables as before. Peak plantarflexion moment (F1, 18 =
8.01, P = 0.01, ES = 0.6) was decreased and peak hip
flexion angle (F1, 18 = 5.59, P =0.03, ES = 0.5) and peak
knee power absorption during early stance (F1, 18 = 5.57,
P = 0.03, ES = 0.5) were significantly increased in NO
REST as compared to REST. Gait speed (F1, 16 = 6.72, P
= 0.02, ES = 0.6) and stride length (F1, 16 = 7.55, P = 0.01,
ES = 0.6) significantly increased in NO REST as compared
to REST. Step width (F1, 16 = 7.44, P = 0.01, ES = 0.6)
significantly decreased in NO REST as compared to REST.
A significant interaction for peak ankle dorsiflexion mo-
ment (F2, 18 = 8.19, P = 0.003) was found (Figure 4C). Pa-
tients with mild to moderate COPD did not change their
dorsiflexion moment (Mean ± standard error: −0.30 ±
0.03 Nm/kg for both) across conditions and patients with
severe to very severe COPD slightly decreased their mo-
ment (−0.34 ± 0.04 Nm/kg to −0.33 ± 0.04 Nm/kg) from
REST to NO REST. Healthy controls increased their
dorsiflexion moment significantly from −0.35 ± 0.02 Nm/
kg to −0.40 ± 0.03 Nm/kg from REST to NO REST.
The last model, #4, stratified patients with COPD into
disease severity and utilized the covariates of age, gender,
and smoking history. A main effect of group was found
for peak ankle power absorption during mid-stance. Pa-
tients with COPD had significantly increased (F2, 31 =
4.34, P = 0.02) power absorption at the ankle in mid-
stance as compared to controls. Follow-up comparisons
reveal that severe/very severe COPD are increased as
compared to controls (t31 = 2.54, P = 0.04, ES = 0.8). No
significant differences were found between mild/moder-
ate compared to controls or mild/moderate compared to
severe/very severe. Significant main effects of condition
found were identical to those found in model #3. Peak
plantarflexion moment (F1, 18 = 8.91, P = 0.008, ES =
0.65) was decreased and peak hip flexion angle (F1, 18 =
5.76, P =0.03, ES = 0.5) and peak knee power absorption
during early stance (F1, 18 = 5.50, P = 0.03, ES = 0.5) were
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Figure 4 Significant interaction for peak ankle dorsiflexion moment in early stance found in model #1 (A), model #2 (B), model #3 (C),
model #4 (D). In A and B, patients with COPD remain relatively stable and healthy controls change from REST to NO REST condition, increasing
(becoming more negative) their peak ankle dorsiflexion moment. In C and D, patients with COPD have been stratified for disease severity and
again, there is a similar pattern. Both mild/moderate and severe/very severe COPD patients maintain a similar peak ankle dorsiflexion moment
from REST to NO REST conditions whereas, the healthy controls increase (become more negative) in NO REST.
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significantly increased in NO REST as compared to
REST. The same spatiotemporal variables also demon-
strated a main effect of condition. Gait speed (F1, 16 =
6.80, P = 0.02, ES = 0.6) and stride length (F1, 16 = 7.51, P
= 0.01, ES = 0.6) significantly increased in NO REST as
compared to REST. Step width (F1, 16 = 7.44, P = 0.01,
ES = 0.6) significantly decreased in NO REST as com-
pared to REST. A significant interaction for peak ankle
dorsiflexion moment (F2, 18 = 8.43, P = 0.003) was found
(Figure 4D). Patients with mild to moderate COPD
(Mean ± standard error: −0.32 ± 0.04 Nm/kg for both
conditions) and severe to very severe COPD (−0.36 ±
0.04 Nm/kg for both conditions) did not change their
dorsiflexion moment across conditions. Healthy controls
increased their dorsiflexion moment significantly from
−0.34 ± 0.03 Nm/kg to −0.40 ± 0.03 Nm/kg from REST
to NO REST.
Discussion
The purpose of this experiment was to characterize bio-
mechanical gait abnormalities in patients with COPD as
compared to their healthy counterparts. Contrary to our
hypothesis, patients with COPD demonstrated minimal
significant differences in biomechanical gait analysis
when walking under a REST condition (only one main
effect of group was found for all dependent variables in
models #1, #2, and #4). Patients with COPD do demon-
strate biomechanical gait changes at the ankle as com-
pared to healthy controls. This was seen not only in
peak ankle power absorption during NO REST but also
patients with COPD demonstrate a lack of increase in
peak ankle dorsiflexion moment from the REST to the
NO REST condition as compared to the healthy con-
trols. We had hypothesized that they would indeed suf-
fer from gait decrements based on our previous findings
[20]. During our previous study, we had investigated the
presence of gait abnormalities reported in the publicly
available NHANES III dataset and the gait abnormalities
reported were subjective and based on observation. The
lack of significant findings in the current study may be
related to the inherent heterogeneity in which COPD
presents itself clinically. Recently, several potential phe-
notypes (subset) of the COPD syndrome have been iden-
tified including a clinical phenotype (age, gender,
smoking history), physiological (rapid decline in FEV1),
radiographic or imaging (structural abnormalities), acute
exacerbation of COPD, systemic inflammation, and the
presence of co-morbidities (cardiovascular disease, meta-
bolic syndrome, osteoporosis, diabetes, depression)
[41,42]. Thus, it cannot yet be concluded that there is
no difference between the gait of healthy controls and
patients with COPD in a REST condition, except at the
ankle, and such differences may be a feature of specific
subset (s) of COPD patients. Further work is needed to
clearly define these differences.
The secondary aim was to examine the effect of NO
REST on the biomechanical gait parameters of patients
with COPD. Based on previous reports of increased
presence of muscular fatigue in patients with COPD
[4,43], we had hypothesized that their gait would signifi-
cantly decrement under a NO REST condition as indu-
cing activity may lead to fatigue. Several parameters
statistically changed from the REST to NO REST condi-
tion for both groups. In the NO REST condition, speed
and stride length increased potentially explaining the in-
creased hip flexion angle and knee power absorption at
early stance during the NO REST condition. Thus, as
the subjects walked faster and took longer steps, their
hip would flex more and the knee would absorb more of
the energy generated from the increased walking speed.
It should be noted that even though both groups walked
faster under the NO REST condition, the mean increases
in gait speed and stride lengths were quite small, al-
though statistically significant. In addition, the peak
ankle plantarflexion moment at push-off decreased for
both groups during the NO REST condition.
Interestingly, a significant interaction was found for
peak ankle dorsiflexion moment at early stance no matter
the statistical model employed. Patients with COPD main-
tained the same amount of torque in their dorsiflexors
from REST to NO REST whereas the healthy controls in-
creased (more negative) their peak dorsiflexion torque in
the NO REST condition. For the healthy controls, this
makes sense as speed has increased in the NO REST con-
dition, an increased dorsiflexion moment would be needed
to control the lowering of the forefoot to the ground.
Based on these findings, it appears that the patients with
COPD may have problems in controlling the foot shortly
after heel strike. Additionally, the longer stride lengths
noted in the NO REST condition may place the tibialis an-
terior under greater mechanical demand and this along
with possible muscular fatigue could account for the lack
of change in patients with COPD. Muscular fatigue during
various physical activities has been reported in patients
with COPD [4,44] and up to 40% of patients present with
muscular fatigue as their main barrier to physical activity
[16]. From the current study, we cannot determine if our
findings are truly due to muscular fatigue. The NO REST
condition was an activity-induced condition and was not a
true fatigue-induced condition and may have been more
of a mild exercise or warm-up type condition. Yet, muscu-
lar fatigue could have been present although this was not
investigated in this study. Future work could investigate
fatigue through more demanding protocols or through the
use of instrumented treadmills, in which steps from the
beginning of a trial are compared to steps at the end of a
trial when fatigue is reported.
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Overall, the models were very similar in findings. Only
slight differences were found with the introduction of
the covariates of age, gender, and smoking history. In
model #1, the hip was found to be significantly different
yet upon adding covariates (model #2), the hip was no
longer significant but the ankle was found to be signifi-
cant. In model #1, the ankle was almost significant, P =
0.07. When the covariates were added, there was a sig-
nificant age effect (P = 0.003), so after adjusting for age,
there was no difference between groups for the hip, that
difference was confounded with age. With the ankle, it
was marginally significant in model #1, and became even
more pronounced after adjusting for the effect of age,
model #2. A similar finding was found with models #3
and #4. A group effect for the ankle was found in model
#4 that was not seen in model #3. Without the covari-
ates (model #3), the ankle was marginally significant P =
0.11, and after adjusting for the effect of age, it became
more pronounced and reached significance. Based upon
these findings, age was the only covariate that had an
impact on the overall findings. This is expected as aging
does have an effect on gait [45]. Gender and smoking
history did not confound any of the findings. Gender dif-
ferences in biomechanical gait studies are typically not
reported; however, a few studies have noted differences
between genders [46,47]. It is interesting to note that
smoking did not affect the findings, as smoking is asso-
ciated with increased systemic inflammation, which is
thought to be a possible mechanism of change in the
structure and function of skeletal muscle in patients with
COPD [48,49].
In COPD, decreased mitochondrial density and frac-
tional area in the vastus lateralis with decreased oxida-
tive enzymes leads to decreased oxidative capacity
[10,50]. Further, oxidative damage, possibly leading to at-
rophy and muscle wasting [51] has been documented,
along with muscle fiber type shifting, where oxidative
fiber type (type-I) shifted to glycolytic fiber types (type-
II) [4,6,52]. In contrast, it has been shown that the more
distal tibialis anterior has normal fractional area and oxi-
dative capacity despite decreased mitochondrial density
[50]. Yet, two recent articles demonstrate that muscle
weakness is present in the ankle dorsiflexors and plan-
tarflexors, greater than weakness present in the quadri-
ceps of patients with COPD [53,54] and that this
weakness is related to changes in muscle structure [54].
Multiple factors could be at play affecting muscle dys-
function and structural changes in COPD [55]. The two
most popular schools of thought are 1) disuse and 2)
chronic systemic inflammation. However, no conclusive
research has yet to be done and appears that possibly a
mix of the two mechanisms may be at play and/or two
phenotypes exist within the disease. In addition, it is
feasible that blood flow and possible changes in blood
gasses that are not generally regarded as clinically im-
portant could also play a role [56]. Although, for patients
with COPD, peripheral muscle oxygenation is not com-
promised during submaximal exercise [57], rather exer-
cise capacity is limited due to disuse and poor lung
function (breathlessness).
A curious and interesting finding during the NO REST
condition is that of the changes in step width. In models
#3 and #4 when disease severity was entered into the
statistical models, it was shown that step width de-
creased significantly in NO REST as compared to REST.
The step width of patients with COPD was narrower in
the NO REST condition as compared to their REST con-
dition. Patients with mild to moderate COPD walked
with a wider step width under both conditions as com-
pared to controls and patients with severe to very severe
COPD. Walking with a wider step could be done as an
attempt to increase the base of support during the
double support phase of gait. As reported in the intro-
duction, fall risk is increased in patients with COPD
[58-61] and changes in step width have been found to be
associated with fall risk [62-65]. It appears though that
step width variability is the dependent variable associ-
ated with fall risk rather than just a mean change in step
width [66-68]. Future studies should examine step width
variability in patients with COPD and the association of
this variability with fall risk and fear of falling.
A limitation of the current study is the heterogeneity
of the manifestations of COPD [69-71]. While COPD is
defined in terms of fixed airflow limitation, COPD is also
characterized by the frequent but extremely variable as-
sociation of disease outside the lungs [72,73]. Among
these, muscle fatigue is a common symptom associated
with mild to moderate COPD patients irrespective of
lung function, anthropometric data or quadriceps
strength [74]. Contributing factors to leg fatigue could
be related to abnormal structure and function of muscle
tissue in COPD [4,6,9,10]. A gauge of exhaustion or fa-
tigue was not utilized in this study and should be
considered in future work. Moreover, several other
co-morbidities have been associated with COPD such as
osteoporosis [75-77], diabetes [78,79], as well as anxiety
and depression [12,80-82], which also associated with
gait abnormalities. This does not include the other phe-
notypes of the disease that have been proposed [41,42].
Likewise, it is possible that our healthy controls did in-
deed have an associated co-morbidity that would likely
result in altered gait mechanics as well. Although all
patients were screened by a nurse practitioner before
inclusion into the study, it is possible that not all
co-morbidities were included in our exclusion criteria.
Future studies should focus on the inclusion of just pa-
tients with severe disease or increase the sample size for
each disease severity.
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Conclusions
The novel finding of this study was that patients with COPD
do indeed demonstrate biomechanical gait alterations when
walking under a NO REST or activity-induced condition.
These documented changes were loss of function at the
ankle joint, in that peak ankle dorsiflexion moment did not
increase under the NO REST condition as it did in the con-
trol sample. Although fatigue was not directly measured in
the current study, it is feasible that the patients with COPD
did present with leg fatigue when activity was induced. Bio-
mechanical gait analysis can provide insight into the joint
muscular responses and contributions to movement, provid-
ing insight into mechanisms of functional limitations in these
patients. Moreover, considering the heterogeneity of COPD,
it is possible that a subset of COPD patients, too small to
have meaningful inclusion in the current study, may manifest
differences not observed in the larger group. Future work
should focus on investigating the effects of muscular fatigue
and associations with biomechanical gait decrements in this
population. In addition, future work should examine bio-
mechanical abnormalities in the different phenotypes associ-
ated with the diagnosis of COPD as some subsets of patients
may present with gait abnormalities and some patients may
not. Lastly, the finding of widened step width in patients with
COPD in the REST condition is of particular interest. The
increased incidence of falls in patients with COPD has been
reported and step width has been indicated as a factor in fall
risk. Further investigations into the association of step width
variability and fear of falling and fall risk in patients with
COPD could reveal significant findings as well as lead to
innovative rehabilitation techniques.
Abbreviations
COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory
volume in one second; FVC: Forced vital capacity; ES: Effect size.
Competing interests
Jennifer Yentes, Kendra Schmid, Debra Romberger, Daniel Blanke and
Nicholas Stergiou have no competing interests. Stephen I. Rennard received
fees for serving on advisory boards, consulting, or honoraria from Almirall,
APT Pharma, Aradigm, Argenta, AstraZeneca, Boehringer Ingelheim, Chiesi,
Dey, Forest, GlaxoSmithKline, Hoffmann-La Roche, MedImmune, Mpex,
Novartis, Nycomed, Oriel, Otsuka, Pearl, Pfizer, Pharmaxis, Merck, and Talecris.
The authors declare that they have no competing interests.
Authors’ contributions
JY conceived the study, carried out all data collections, data reduction,
processing, analysis, and writing of the manuscript. KS performed the statistical
analysis and writing of the manuscript. DR and DB revised the manuscript
critically for important intellectual content. SI and NS assisted in the conception
of the study, and participated in its design and coordination, and helped to
revise the manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors would like to thank Mary Carlson, NP for her assistance in screening
all of the subjects and Jeff Kaipust, MS for his assistance with data collections.
Funding provided by American Society of Biomechanics Grant-in-Aid, American
Alliance for Health, Physical Education, Recreation and Dance Graduate Student
Grant-in-Aid, NASA Nebraska Space Grant Fellowship program and Research
Support Fund from the Nebraska Medical Center and the University of Nebraska
Medical Center. Additional funding provided by the National Institutes of Health
(P20 GM109090). Funding sources had no involvement in study design, data
interpretation, and/or manuscript preparation.
Author details
1Biomechanics Research Building, University of Nebraska at Omaha, 6001
Dodge Street, Omaha, NE 68182-0860, USA. 2College of Public Health,
University of Nebraska Medical Center, 984355 Nebraska Medical Center,
Omaha, NE 68198, USA. 3Nebraska-Western Iowa Veterans’ Health Care
System; U.S. Department of Veterans’ Affairs, 4101 Woolworth Avenue,
Omaha, NE 68105, USA. 4Department of Pulmonary and Critical Care
Medicine, University of Nebraska Medical Center, 036 DRC2, Omaha, NE
68198-5910, USA.
Received: 17 November 2014 Accepted: 4 February 2015
References
1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk
factors: Global Burden of Disease Study. Lancet. 1997;349(9063):1436–42.
2. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory
syndrome? Lancet. 2007;370(9589):797–9.
3. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al.
Skeletal muscle dysfunction in chronic obstructive pulmonary disease A
statement of the American Thoracic Society and European Respiratory
Society. Am J Respir Crit Care Med. 1999;159(4):S1–40.
4. Allaire J, Maltais F, Doyon J, Noël M, LeBlanc P, Carrier G, et al. Peripheral
muscle endurance and the oxidative profile of the quadriceps in patients
with COPD. Thorax. 2004;59(8):673–8.
5. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, et al.
Peripheral muscle weakness in patients with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 1998;158(2):629–34.
6. Gosker HR, van Mameren H, van Dijk PJ, Engelen MPKJ, van der Vusse GJ,
Wouters EFM, et al. Skeletal muscle fibre-type shifting and metabolic profile
in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19
(4):617–25.
7. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom
intensity, and exercise capacity in patients with cardiorespiratory disorders.
Am J Respir Crit Care Med. 1995;152(6):2021–31.
8. Hamilton AL, Killian KJ, Summers E, Jones NL. Symptom intensity and
subjective limitation to exercise in patients with cardiorespiratory disorders.
Chest. 1996;110(5):1255–63.
9. Mador MJ, Deniz O, Aggarwal A, Kufel TJ. Quadriceps fatigability after single
muscle exercise in patients with chronic obstructive pulmonary disease. Am
J Respir Crit Care Med. 2003;168(1):102–8.
10. Maltais F, LeBlanc P, Whittom F, Simard C, Marquis K, Bélanger M, et al.
Oxidative enzyme activities of the vastus lateralis muscle and the functional
status in patients with COPD. Thorax. 2000;55(10):848–53.
11. Wouters EFM, Creutzberg EC, Schols AMWJ. Systemic effects in COPD.
Chest. 2002;121(5):127S–30s.
12. Peruzza S, Sergi G, Vianello A, Pisent C, Tiozzo F, Manzan A, et al. Chronic
obstructive pulmonary disease (COPD) in elderly subjects: impact on
functional status and quality of life. Respir Med. 2003;97(6):612–7.
13. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical
activity and hospitalization for exacerbation of COPD. Chest. 2006;129(3):536–44.
14. Garcia-Aymerich J, Félez MA, Escarrabill J, Marrades RM, Morera J, Elosua R,
et al. Physical activity and its determinants in severe chronic obstructive
pulmonary disease. Med Sci Sports Exerc. 2004;36(10):1667–73.
15. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R.
Characteristics of physical activities in daily life in chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–7.
16. Saey D, Debigare R, LeBlanc P, Mador MJ, Cote CH, Jobin J, et al. Contractile leg
fatigue after cycle exercise: a factor limiting exercise in patients with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168(4):425–30.
17. Gagnon P, Saey D, Vivodtzev I, Laviolette L, Mainguy V, Milot J, et al. Impact
of preinduced quadriceps fatigue on exercise response in chronic
obstructive pulmonary disease and healthy subjects. J Appl Physiol.
2009;107(3):832–40.
18. Alexandre F, Heraud N, Oliver N, Varray A. Cortical implications in lower
voluntary muscle force production in non-hypoxemic COPD patients. PLoS
One. 2014;9(6):e100961.
Yentes et al. Respiratory Research  (2015) 16:31 Page 11 of 13
19. Debigare R, Maltais F. The major limitation to exercise performance in COPD
is lower limb muscle dysfunction. J Appl Physiol. 2008;105(2):751–3.
20. Yentes JM, Sayles H, Meza J, Mannino DM, Rennard SI, Stergiou N. Walking
abnormalities are associated with COPD: an investigation of the NHANES III
dataset. Respir Med. 2011;105(1):80–7.
21. Annegarn J, Spruit MA, Savelberg HHCM, Willems PJB, Van DB, Schols
AMWJ, et al. Differences in walking pattern during 6-min walk test between
patients with COPD and healthy subjects. PLoS One. 2012;7(5):e37329.
22. Winter D. Biomechanics and Motor Control of Human Movement. John
Wiley & Sons, Inc: Hoboken, New Jersey; 2005.
23. Baker R, Robb J. Foot models for clinical gait analysis. Gait Posture. 2006;23
(4):399–400.
24. Fosang A, Baker R. A method for comparing manual muscle strength
measurements with joint moments during walking. Gait Posture. 2006;24
(4):406–11.
25. Chang FF, Seidl AJ, Muthusamy K, Meininger AK, Carollo JJ. Effectiveness of
instrumented gait analysis in children with cerebral palsy–comparison of
outcomes. J Pediatr Orthop. 2006;26(5):612–6.
26. Kawamura CM, de Morais Filho MC, Barreto MM, de Paula Asa SK, Juliano Y,
Novo NF. Comparison between visual and three-dimensional gait analysis in
patients with spastic diplegic cerebral palsy. Gait Posture. 2007;25(1):18–24.
27. Romkes J, Hell AK, Brunner R. Changes in muscle activity in children with
hemiplegic cerebral palsy while walking with and without ankle-foot orth-
oses. Gait Posture. 2006;24(4):467–74.
28. McGinley JL, Morris ME, Greenwood KM, Goldie PA, Olney SJ. Accuracy of
clinical observations of push-off during gait after stroke. Arch Phys Med
Rehabil. 2006;87(6):779–85.
29. Tenore N, Fortugno F, Viola F, Galli M, Giaquinto S. Gait analysis as a reliable
tool for rehabilitation of chronic hemiplegic patients. Clin Exp Hypertens.
2006;28(3–4):349–55.
30. Yavuzer G, Eser F, Karakus D, Karaoglan B, Stam HJ. The effects of balance
training on gait late after stroke: a randomized controlled trial. Clin Rehabil.
2006;20(11):960–9.
31. Basford JR, Chou L, Kaufman KR, Brey RH, Walker A, Malec JF, et al. An
assessment of gait and balance deficits after traumatic brain injury. Arch
Phys Med Rehabil. 2003;84(3):343–9.
32. Horn TS, Yablon SA, Stokic DS. Effect of intrathecal baclofen bolus injection
on temporospatial gait characteristics in patients with acquired brain injury.
Arch Phys Med Rehabil. 2005;86(6):1127–33.
33. Vallée M, McFadyen BJ, Swaine B, Doyon J, Cantin J, Dumas D. Effects of
environmental demands on locomotion after traumatic brain injury. Arch
Phys Med Rehabil. 2006;87(6):806–13.
34. Runge M, Hunter G. Determinants of musculoskeletal frailty and the risk of
falls in old age. J Musculoskelet Neuronal Interact. 2006;6(2):167–73.
35. Kerr C, McDowell B, Cosgrove A, Walsh D, Bradbury I, McDonough S.
Electrical stimulation in cerebral palsy: a randomized controlled trial. Dev
Med Child Neurol. 2006;48(11):870–6.
36. Barker SP, Freedman W, Hillstrom H. A novel method of producing a
repetitive dynamic signal to examine reliability and validity of gait analysis
systems. Gait Posture. 2006;24(4):448–52.
37. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al.
Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med. 2013;187(4):347–65.
38. Houck JR, Duncan A, De Haven KE. Knee and hip angle and moment
adaptations during cutting tasks in subjects with anterior cruciate ligament
deficiency classified as noncopers. J Orthop Sports Phys Ther. 2005;35
(8):531–40.
39. Jackson KM. Fitting of mathematical functions to biomechanical data. IEEE
Trans Biomed Eng. 1979;26(2):122–4.
40. Dempster W. Space Requirements of the Seated Operator: Geometrical,
Kinematic, and Mechanical Aspects of the Body With Special Reference to
the Limbs. Dayton, OH: WADC Technical Report; 1955.
41. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic
obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir
Crit Care Med. 2010;182(5):598–604.
42. Chen X, Xu X, Xiao F. Heterogeneity of chronic obstructive pulmonary
disease: from phenotype to genotype. Front Med. 2013;7(4):425–32.
43. Marquis N, Debigaré R, Bouyer L, Saey D, Laviolette L, Brouillard C, et al.
Physiology of walking in patients with moderate to severe chronic
obstructive pulmonary disease. Med Sci Sports Exerc. 2009;41:1540–8.
44. Saey D, Côté CH, Mador MJ, Laviolette L, LeBlanc P, Jobin J, et al.
Assessment of muscle fatigue during exercise in chronic obstructive
pulmonary disease. Muscle Nerve. 2006;34(1):62–71.
45. DeVita P, Hortobagyi T. Age causes a redistribution of joint torques and
powers during gait. J Appl Physiol. 2000;88(5):1804–11.
46. Bruening, DA, Frimenko, RE, Goodyear, CD, Bowden, DR, Fullenkamp, AM.
Sex differences in whole body gait kinematics at preferred speeds. Gait and
Posture 2014; doi:10.1016/j.gaitpost.2014.12.011.
47. Kerrigan DC, Todd MK, Della Croce U. Gender differences in joint
biomechanics during walking: normative study in young adults. Am J Phys
Med Rehabil. 1998;77(1):2–7.
48. Degens, H, Gayan-Ramirez, G, van Hees, HWH. Smoking-induced skeletal
muscle dysfunction: From evidence to mechanisms. American Journal of
Respiratory Critical Care Medicine 2015; doi: 10.1164/rccm.201410-1830PP.
49. Caron M, Morissette MC, Theriault M, Nikota JK, Shen P, Staempfli MR, et al.
Altered skeletal muscle homeostasis in a Pre-clinical model of cigarette
smoke exposure. Am J Respir Crit Care Med. 2011;183:A2529.
50. Gosker HR, Hesselink MK, Duimel H, Ward KA, Schols AM. Reduced
mitochondrial density in the vastus lateralis muscle of patients with COPD.
Eur Respir J. 2007;30(1):73–9.
51. Allaire J, Maltais F, LeBlanc P, Simard P, Whittom F, Doyon J, et al. Lipofuscin
accumulation in the vastus lateralis muscle in patients with chronic
obstructive pulmonary disease. Muscle Nerve. 2002;25(3):383–9.
52. Whittom F, Jobin J, Simard PM, Leblanc P, Simard C, Bernard S, et al.
Histochemical and morphological characteristics of the vastus lateralis
muscle in patients with chronic obstructive pulmonary disease. Med Sci
Sports Exerc. 1998;30(10):1467–74.
53. Gagnon P, Maltais F, Bouyer L, Ribeiro F, Coats V, Brouillard C, et al. Distal
leg muscle function in patients with COPD. COPD. 2013;10(2):235–42.
54. Maddocks M, Jones M, Snell T, Connolly B, de Wolf-Linder S, Moxham J,
et al. Ankle dorsiflexor muscle size, composition and force with ageing and
chronic obstructive pulmonary disease. Exp Physiol. 2014;99(8):1078–88.
55. Wüst RCI, Degens H. Factors contributing to muscle wasting and
dysfunction in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2
(3):289–300.
56. Aliverti A, Macklem PT. Point: counterpoint: the major limitation to exercise
performance in COPD is: 1) inadequate energy supply to the respiratory and
locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic
hyperinflation. J Appl Physiol. 2008;105(2):749–51.
57. Austin KG, Mengelkoch L, Hansen J, Shahady E, Sirithienthad P, Panton L.
Comparison of oxygenation in peripheral muscle during submaximal
aerobic exercise, in persons with COPD and healthy, matched-control
persons. Int J Chron Obstruct Pulmon Dis. 2006;1(4):467–75.
58. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T, Brooks D. Impairments
in balance discriminate fallers from non-fallers in COPD. Respir Med. 2009;103
(12):1885–91.
59. Beauchamp MK, Sibley KM, Lakhani B, Romano J, Mathur S, Goldstein RS,
et al. Impairments in systems underlying control of balance in COPD. Chest.
2012;141(6):1496–503.
60. Janssens L, Brumagne S, McConnell AK, Claeys K, Pijnenburg M, Burtin C,
et al. Proprioceptive changes impair balance control in individuals with
chronic obstructive pulmonary disease. PLoS One. 2013;8(3):e57949.
61. Ozalevli S, Ilgin D, Narin S, Akkoclu A. Association between disease-related
factors and balance and falls among the elderly with COPD: a cross-
sectional study. Aging Clin Exp Res. 2011;23(5–6):372–7.
62. Nordin E, Moe-Nilssen R, Ramnemark A, Lundin-Olsson L. Changes in step-
width during dual-task walking predicts falls. Gait Posture. 2010;32(1):92–7.
63. Schulz BW. Healthy younger and older adults control foot placement to
avoid small obstacles during gait primarily by modulating step width. J
Neuroeng Rehabil. 2012;9:69-0003-9-69.
64. Schrager MA, Kelly VE, Price R, Ferrucci L, Shumway-Cook A. The effects of
age on medio-lateral stability during normal and narrow base walking. Gait
Posture. 2008;28(3):466–71.
65. Dean JC, Alexander NB, Kuo AD. The effect of lateral stabilization on walking
in young and old adults. IEEE Trans Biomed Eng. 2007;54(11):1919–26.
66. Owings TM, Grabiner MD. Step width variability, but not step length
variability or step time variability, discriminates gait of healthy young and
older adults during treadmill locomotion. J Biomech. 2004;37(6):935–8.
67. Brach JS, Studenski S, Perera S, VanSwearingen JM, Newman AB. Stance
time and step width variability have unique contributing impairments in
older persons. Gait Posture. 2008;27(3):431–9.
Yentes et al. Respiratory Research  (2015) 16:31 Page 12 of 13
68. Brach JS, Berlin JE, VanSwearingen JM, Newman AB, Studenski SA. Too
much or too little step width variability is associated with a fall history in
older persons who walk at or near normal gait speed. J Neuroeng Rehabil.
2005;2:21.
69. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D,
et al. COPD as a lung disease with systemic consequences–clinical impact,
mechanisms, and potential for early intervention. COPD. 2008;5(4):235–56.
70. Rennard SI. COPD heterogeneity: what this will mean in practice. Respir
Care. 2011;56(8):1181–7.
71. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur
Respir J. 2009;33(5):1165–85.
72. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med.
2005;26(2):142–53.
73. Sin DD, Man SFP. Skeletal muscle weakness, reduced exercise tolerance, and
COPD: is systemic inflammation the missing link? Thorax. 2006;61(1):1–3.
74. Coronell C, Orozco-Levi M, Méndez R, Ramírez-Sarmiento A, Gáldiz JB, Gea J.
Relevance of assessing quadriceps endurance in patients with COPD. Eur
Respir J. 2004;24(1):129–36.
75. Biskobing DM. COPD and osteoporosis. Chest. 2002;121(2):609–20.
76. Ciric Z, Stankovic I, Pejcic T, Ristic L, Rancic M, Radovic M. Osteoporosis in
patients with chronic obstructive pulmonary disease. Med Arh. 2012;66
(6):385–7.
77. Romme EA, Rutten EP, Geusens P, de Jong JJ, van Rietbergen B, Smeenk
FW, et al. Bone stiffness and failure load are related with clinical parameters
in men with chronic obstructive pulmonary disease. J Bone Miner Res.
2013;28(10):2186–93.
78. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of
diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J.
2008;32(4):962–9.
79. Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid Diabetes
and COPD: Impact of corticosteroid use on diabetes complications.
Diabetes Care. 2013;36(10):3009–14.
80. Hellstrom K, Vahlberg B, Urell C, Emtner M. Fear of falling, fall-related self-efficacy,
anxiety and depression in individuals with chronic obstructive pulmonary disease.
Clin Rehabil. 2009;23(12):1136–44.
81. Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in
patients with chronic obstructive pulmonary disease (COPD). A review Nord
J Psychiatrys. 2004;58(1):65–70.
82. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between
depression and exacerbations in COPD. Eur Respir J. 2008;32(1):53–60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yentes et al. Respiratory Research  (2015) 16:31 Page 13 of 13
